Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2019 16:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures

WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on...
November 14, 2019 08:30 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice

-- Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....
October 07, 2019 08:30 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair

WESTLAKE VILLAGE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a...
September 17, 2019 08:30 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding

WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a...
August 05, 2019 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strategic Alternatives

WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained...
June 20, 2019 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference

WESTLAKE VILLAGE, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield...
June 10, 2019 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology

-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....
May 21, 2019 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe

WESTLAKE VILLAGE, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul, M.D.,...
May 14, 2019 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis

-- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120 -- Following Positive End-of-Phase 2 meeting with FDA, Sienna continues toward enrolling first patient in Phase...
May 09, 2019 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals to Present at BAML Health Care Conference

WESTLAKE VILLAGE, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief...

Next Page keyboard_arrow_right